Skip to main content
. 2015 Oct 21;13(4):295–305. doi: 10.1016/j.aju.2015.09.003

Figure 3.

Figure 3

Patient survival of the recipients who did not develop GN vs recipients who developed PTGN. (A) Patient survival in the recipients who developed PTGN (dashed line) was comparable to those with no PTGN (solid line) in the first 5 years. Thereafter, there was a significant drop in patient survival in the group of recipients who had PTGN vs those who did not develop PTGN (P = 0.048). (B) patient survival in the recipients who developed PTGN (whatever the cause) was comparable to those who did not develop PTGN in the first 5 years. Thereafter, there was a significant drop in patient survival in the group of recipients who had de novo GN (dashed line) and transplant glomerulopathy (solid line) vs those who did not develop PTGN (P = 0.005).